GSK2245035
- Generic Name
- GSK2245035
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H34N6O2
- CAS Number
- 1207629-49-9
- Unique Ingredient Identifier
- 5L3SX16QBQ
- Background
GSK2245035 is under investigation in clinical trial NCT02833974 (Effect of the GSK2245035 on the Allergen-induced Asthmatic Response).
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2018-10-16
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03707678
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT01788813
- Locations
- 🇨🇦
GSK Investigational Site, Kingston, Ontario, Canada
A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-30
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT01607372
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath